

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A method for inhibition of pathological angiogenesis in a tissue prone to pathological angiogenesis and expressing $\alpha 6 \beta 4$ integrin, comprising the steps of exposing the tissue to a therapeutic agent effective to reduce the amount of active $\alpha 6 \beta 4$ integrin in the tissue, wherein the therapeutic agent targets and inhibits the signaling function of $\beta 4$, thereby inhibiting pathological angiogenesis.
2. (original) The method of claim 1, wherein the tissue is present in a living organism.
3. (previously presented) The method of claim 2, wherein the living organism is human.
4. (canceled)
5. (previously presented) The method of claim 1, wherein the therapeutic agent is an antibody.
6. (withdrawn) The method of claim 1, wherein the therapeutic agent is an RNAi species.
7. (previously presented) A method for treatment of a disease condition associated with pathological angiogenesis in a patient, comprising the step of administering to the patient an amount of a therapeutic agent effective to reduce the amount of active $\alpha 6 \beta 4$ integrin, wherein the therapeutic agent targets and inhibits the signaling function of $\beta 4$ thereby inhibiting pathological angiogenesis.

8. (previously presented) The method of claim 7 wherein the patient is human.
9. (previously presented) The method of claim 8, wherein the therapeutic agent is an antibody.
10. (withdrawn) The method of claim 8, wherein the therapeutic agent is an RNAi species.
- 11-14. (canceled)
15. (previously presented) The method of claim 7, wherein the therapeutic agent is an antibody.
16. (withdrawn) The method of claim 7, wherein the therapeutic agent is an RNAi species.
17. (previously presented) The method of claim 3, wherein the therapeutic agent is an antibody.
18. (withdrawn) The method of claim 3, wherein the therapeutic agent is an RNAi species.
19. (previously presented) The method of claim 1, wherein the therapeutic agent is an antibody.
20. (withdrawn) The method of claim 1, wherein the therapeutic agent is an RNAi species.
21. (new) A method for inhibition of pathological angiogenesis in a tissue prone to pathological angiogenesis and expressing $\alpha 6\beta 4$ integrin, comprising the steps of exposing the

Appln No.: 10/595,845

Reply to Office Action of 10/17/2008

tissue to an antibody that targets and inhibits the signaling function of $\beta 4$, thereby inhibiting pathological angiogenesis.

22. (new) The method of claim 21 wherein the tissue comprises one or more chosen from the group consisting of: human papillary thyroid carcinoma, breast adenocarcinoma, prostate carcinoma, lung carcinoma, glioblastoma multiforme, melanoma, and lymphoma.

23. (new) The methods of claim 21 wherein the antibody targets the C-terminal end of $\beta 4$, wherein the C-terminal end begins at amino acid residue 1355.